Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Finranks

Компания

  • О нас

Контакты

  • [email protected]

Мы в соцсетях

  • Instagram
  • Telegram
  • LinkedIn

Все права защищены.

Условия использования
  • Главная
  • Рынки
  • Скринер
  • Новости
  • О нас
  1. Home
  3. KRMD
K

KORU Medical Systems, Inc. (KRMD)

NCM – Цена в реальном времени. Валюта: USD

4.22

-0.14 (-3.21%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

4.22

0.00 (0.00%)

После закрытия: Mar 27, 2026, 4:10 PM EDT

  • Обзор
  • Новости
  • График
  • Финансы
  • Дивиденды
  • Прогноз
  • Владельцы
  • Профиль

Видео

No Data

There is no data to display

Пресс-релизы

KORU Medical Systems Announces EU MDR Certification for the Freedom60® Infusion Pump With Prefilled Syringe Compatibility
13.03.2026

KORU Medical Systems Announces EU MDR Certification for the Freedom60® Infusion Pump With Prefilled Syringe Compatibility

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that its Freedom60® Infusion Pump, including adapter for use with 50 mL prefilled syringes, has achieved certification under the European Union Medical Devices Regulation (EU MDR 2017/745), ena.

KORU Medical Systems Announces CEO Transition
12.03.2026

KORU Medical Systems Announces CEO Transition

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that following five years of service to the Company, Linda Tharby, President and Chief Executive Officer, will retire effective June 30, 2026. The Board of Directors has appointed Adam Kalberma.

KORU Medical Systems Announces +20% Fourth Quarter and Full Year 2025 Revenue Growth, Positive Adjusted EBITDA and Initiates Full Year 2026 Guidance
12.03.2026

KORU Medical Systems Announces +20% Fourth Quarter and Full Year 2025 Revenue Growth, Positive Adjusted EBITDA and Initiates Full Year 2026 Guidance

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025. The Company also initiated guidance for the full year 2026. Recent Highlights Fourth quarter 2025 net revenues gre.

KORU Medical Systems Receives FDA 510(k) Clearance for Delivery of RYSTIGGO® (rozanolixizumab-noli), Expanding Label for FreedomEDGE® Infusion System
29.01.2026

KORU Medical Systems Receives FDA 510(k) Clearance for Delivery of RYSTIGGO® (rozanolixizumab-noli), Expanding Label for FreedomEDGE® Infusion System

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company received U.S. Food and Drug Administration (FDA) clearance for use of the KORU Medical FreedomEDGE® infusion system to deliver RYSTIGGO® (rozanolixizumab-noli), a therapy comme.